Black patients with psoriasis had the lowest rate of switching to another biologic therapy compared with other racial and ethnic groups, suggesting possible disparities in treatment patterns.
Review found that fewer than 60% of patients with chronic inflammatory skin diseases underwent recommended testing before starting systemic immunomodulator treatment.